Bendamustine (hydrochloride hydrate)

• Description:

  Bendamustine hydrochloride hydrate (SDX-105 hydrate), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride hydrate activates DNA-damage stress response and apoptosis. Bendamustine hydrochloride hydrate has potent alkylating, anticancer and antimetabolite properties[1].

• Product Name Alternative:

  SDX-105 (hydrate)

• UNSPSC:

  12352005

• Target:

  Apoptosis; DNA Alkylator/Crosslinker

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Smiles:

  O=C(CCCC1=NC2=C(N1C)C=CC(N(CCCl)CCCl)=C2)O.Cl.O

• Molecular Formula:

  C16H24Cl3N3O3

• Molecular Weight:

  412.74

• References & Citations:

  [1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14 (1) :309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25 (5) :1108-17. |[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167 (4) :881-91.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1374784-02-7]